Download Chemoradiotherapy for Rectal cancer

Document related concepts
no text concepts found
Transcript
Chemoradiotherapy
for Rectal cancer
Dr. A . Sun Myint
Lead Clinician GI Tumour Group
Clatterbridge Centre for Oncology
Association of Coloproctology of Great Britain and Ireland
M62 Coloproctology Course - March 23rd 2007
Background
•
•
•
•
•
•
In the UK over 10,000 new rectal cancer
Five year survival 50% (NBOCAP-2006)
Nearly half will develop recurrences
At presentation 30% T3/T4 N + MO
Preoperative radiotherapy reduce LR
So far, no survival advantage
Treatment Options
Options
• Surgery
• Radiotherapy
• Chemotherapy
Improvements
TME / Training
Sub specialisation
Pre operative
Chemoradiotherapy
Post operative
Advance /metastatic
Adjuvant
New agents
Radiotherapy
Preoperative Radiotherapy
Short course or Long course?
• Short course
• Long course
Preoperative Radiotherapy
Short course or Long course?
• Short course - Mobile operable tumour
• Long course - Fixed / Tethered tumour
30%( MRI defined CRM +)
Preoperative Radiotherapy
Short course or Long course?
• Short course - Mobile operable tumour
• Long course - Fixed / Tethered tumour
( MRI defined CRM +)
Improving Outcomes
• Add chemotherapy to radiation
• Increase radiation dose
Chemo-radiotherapy
Concurrent Chemotherapy + RT
•
•
•
•
•
5FU
5FU / FA
5FU infusion + Irino / Oxaliplatin
Capecitabine + Irino / Oxaliplatin+ EGFR
Capecitabine + Irino / Oxaliplatin+ VEGFR
Oxaliplatin is a radiosensitiser
in HT-29 xenograft models
Tumour volume
160
Control
120
Oxaliplatin 5mg/kg
80
Radiation only (5Gy)
40
Oxaliplatin + radiation
0
01
05
09
13
17
Days post-treatment
21
Blackstock A et al. Int J Rad Oncol Biol Phys 2000;16:92–94
Comparative tumor sterilization rate
by treatment modality
Treatment
modality
pCR + pMic
RO
EBRT alone
7.1% (26%)
40%
EBRT+ chemo
16.2% (31%)
60%
EBRT+ duplet
21% (60%)
90%
Is chemo-Radiotherapy
better than RT alone?
EORTC Rectal cancer trial
T3/T4 rectal cancer
n=1011
Pre-op RT
SURGERY
Pre-op
Chemo/RT
SURGERY
Pre-op RT
SURGERY
Adjuvant
Chemo
Pre-op
Chemo/RT
SURGERY
Adjuvant
Chemo
EORTC Rectal cancer trial
Local
recurrence
Pre-op
Chemo/RT
Pre-op RT
8.7%
17%
(p=0.0016)
Bossett al ASCO 2005
EORTC Rectal cancer trial
Adjuvant
Chemo
Survival
Bossett al ASCO 2005
67.2%
No Adjuvant
Chemo
63.2%
FFCD 9203- Rectal cancer trial
T3/T4 rectal cancer
n=733
Pre-op RT
SURGERY
Pre-op CRT
SURGERY
JP Gerard et al ASCO 2005
Ad Chemo
Ad Chemo
FFCD 9203- Rectal cancer trial
Pre-op
Chemo/RT
Local
recurrence
8.0%
JP Gerard et al ASCO 2005
Pre-op RT
16.5%
FFCD 9203- Rectal cancer trial
Adjuvant
Chemo
Survival
67%
JP Gerard et al ASCO 2005
No Adjuvant
Chemo
66%
Chemo RT vs. Radiotherapy
Local control in T3/T4 rectal cancer
Trials
Pre-op CRT
Pre-op RT
EORTC 22921
8.7%
17.1%
FFCD 9203
8%
16.5%
German-94
6%
Pre-operative
Radiotherapy better than
post op RT?
German pre op. vs. post operative
chemoradiotherapy for rectal cancer
Preoperative
Chemo-RT
Surgery
Surgery
Post operative
Chemo-RT
Sauer et al N Engl J Med (2004) 351;17 1731-01740
German pre op. vs. post operative
chemoradiotherapy for rectal cancer
Pre op
Local
recurrence
Survival
Post op
n=405
n=394
6%
13%
P=0.0006
76%
74%
P=0.08
Sauer et al N Engl J Med (2004) 351;17 1731-01740
German pre op. vs. post operative
chemoradiotherapy for rectal cancer
Pre op
Acute
Toxicity
Late
Toxicity
Post op
n=405
n=394
27%
40%
P=0.001
14%
24%
P=0.01
Sauer et al N Engl J Med (2004) 351;17 1731-01740
Newer agents for
chemoradiotherapy
Chemoradiotherapy
•
•
•
•
•
•
•
5FU bolus
5FU+ FA
Infusional 5FU
Capecitabine
Irinotecan +Cape
Oxaliplatin +Cape
Triplet therapy
R
A
D
I
O
T
H
E
R
A
P
Y
NWCCOG 1+ RICE
CORE/ SOCRATES
Ir/Oxali + MdG+ VEGF
Pre-operative
5-FU chemoradiation:
• 5-FU-based chemoradiation has become part of
standard pre-operative therapy for rectal cancer
– effective downstaging
– 10–30% pCR rates
• Protracted infusion of 5-FU with postoperative
radiotherapy
improves survival versus bolus
1
5-FU
1O’Connell
MJ et al. N Engl J Med 1994;331:502–7
Infused versus bolus 5-FU during
pelvic radiation
Overall survival (%)
Infused 5-FU (n=328)
100
Bolus 5-FU (n=332)
80
60
Log rank p=0.005
Cox model p=0.01
40
20
0
0
1
2
3
4
Years after randomisation
O’Connell MJ et al. N Engl J Med 1994;331:502–7
Capecitabine + radiation
capecitabine plus radiotherapy
• Infused 5-FU is cumbersome and inconvenient
for patients
• Oral capecitabine simplifies chemoradiation and
is highly appealing to patients
• Potential for enhanced therapeutic ratio
– capecitabine generates 5-FU preferentially
in
1
tumour via thymidine phosphorylase (TP)
– radiotherapy further upregulates TP in tumour
1Miwa
2Sawada
2
M et al. Eur J Cancer 1998;34:1274–81
N et al. Clin Cancer Res 1999;5:2948–53
Irradiation upregulates TP
TP (units/mg protein)
5Gy
25
2.5Gy
*
20
Control
*
15
*
*
10
*
5
*
*
*
*
0
0
*p<0.05
3
6
9
12
15
Days after X-ray irradiation
18
21
Sawada N et al. Clin Cancer Res 1999;5:2948–53
capecitabine enhances activity of
radiation in WiDr xenografts,
Tumour
inhibition (%)
120
*
100
80
60
40
20
0
*p<0.05
Sawada N et al. Clin Cancer Res 1999;5:2948–53
Capecitabine chemoradiation:
• Oral capecitabine is replacing 5-FU in
chemoradiation
– capecitabine is highly effective and well
tolerated in combination with radiotherapy
– capecitabine simplifies chemoradiation and is
highly appealing to patients and clinicians alike
Chemoradiation in rectal cancer:
German phase II study (n=68)
Day
1
8
15
22
29
35
50.4Gy radiotherapy
1.8Gy / fraction
825mg/m2
twice daily
Continuous (days 1–37)
• Male / female (%)63 / 37
• Median age
65 years
• ECOG 0/1 (%)
54 / 41
• T3 / T4 (%)48 / 52 (57% N1–3)
Dunst J et al. Proc Am Soc Clin Oncol 2003;22:277 (Abst 1113)
capecitabine
chemoradiation:efficacy
Patients (%)
1
2
Dunst study
Lin study
Down staging
79
73
pRR
80
87
pCR
5
20
1Dunst
2Lin
J et al. Eur J Cancer 2003;1(Suppl. 5):S86 (Abst 282)
E et al. Proc Am Soc Clin Oncol 2003;22:287 (Abst 1152)
capecitabine chemoradiation:
Toxicity
Patients (%)
80
• No grade 4 adverse events
60
Grade 1/2
40
Grade 3
20
0
Diarrhoea
Local
erythema
Pain
Hand-foot
syndrome
Nausea
Dunst J et al. Eur J Cancer 2003;1(Suppl. 5):S86 (Abst 282)
NSABP R-04
rectal cancer trial
Objectives
–
–
–
–
DFS
recurrence rate
pCR
safety
capecitabine continuously
throughout
radiotherapy (50.4Gy*)
Resectable rectal
cancer, stage II–III
n=1600
5-FU continuous
infusion throughout
radiotherapy (50.4Gy*)
*Plus 5.4Gy for fixed tumours
S
U
R
G
E
R
Y
Chemoradiation using
Oxaliplatin combination
capecitabine/oxaliplatin
chemoradiation
Patients (%)
Glynne-Jones
(n=16)
1
2
Rödel
(n=31)
pCR
31
19
pT1 / 2N0
19
23
R0
88
94
R1
12
6
Resection margin
1Glynne-Jones
R et al. Proc Am Soc Clin Oncol 2003;22:292 (Abst 1174)
2Rödel C et al. J Clin Oncol 2003;21:3098–104
CORE: European study
Day
1
8
15
22
29
Radiotherapy
45Gy / 25 fractions
capecitabine
825mg/m twice daily
Monday to Friday
2
Oxaliplatin
50mg/m
weekly
2
 CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
Chemoradiotherapy using
Irinotecan combination
RICE - NWCCOG study
Day
1
8
15
22
29
Radiotherapy
45Gy / 25 fractions
capecitabine
825mg/m twice daily
Monday to Friday
2
IRINOTECAN
60mg/m2 weekly
S. Gollins, S.Myint, E. Levine et al Proc Am Soc Clin Oncol 2006;24:617s (Abst 13519)
Chemoradiotherapy
•
•
•
•
•
•
•
5FU bolus
5FU+ FA
Infusional 5FU
Capecitabine
Irinotecan +Cape
Oxaliplatin +Cape
Triplet therapy
R
A
D
I
O
T
H
E
R
A
P
Y
NWCCOG 1+ RICE
CORE/ SOCRATES
Ir/ Oxali + cape+ EGF
ARISTOTLE
Reducing Toxicity from CRT
Toxicity
•
•
Chemoradiotherapy is more toxic than
radiotherapy alone
To reduce toxicity:Preoperative rather than post op
Radiation volume
Dose, fractionation and time
Radiation techniques
Are there any other options to
reduce toxicity
from chemoradiation?
Improving Outcomes
• Add chemotherapy to radiation
• Increase radiation dose
Increasing Radiation dose
• External Beam ( 45 Gy /25# /35)
• EBRT +Boost ( 50.4Gy/28#/38)
• EBRT + Contact RT boost (60-80Gy)
• EBRT + Contact HDR boost
Papillon Technique
Radical contact radiotherapy
Lyon R96-02 Trial
Results
EBRT
Clinical CR
( 2% )
Path CR/micro (34%)
Sphincter
(44%)
EBRT+ boost
(24%)
(57%)p=.027
(76%)p=.004
JP Gerard et al. J Clin Oncol 2004 :22 2404-2409
Lyon R96-02 Trial
Results
EBRT
LR
Morbidity
LR Survival
3%
43%
88%
EBRT + Boost
1%
38%
92%
JP Gerard et al J Clin Oncol 2004 :22 2404-2409
HDR Rectal
Brachytherapy
20mm
5mm
Pre op HDR Brachytherapy
Pathology
•
•
•
•
T0N0
Micro
Residual
N+
29%
37%
34%
31%
• T. Vuong et at. I.J. Rad Onc. Bio. Phys vol60:no1 supp; 2004 abst:
1062
Pre op HDR Brachytherapy
Results
• Median FU 37months
• 5years Local recurrence
DFS
OS
CSS
• Toxicity G3
3%
65%
74%
84%
1% (30% CRT)
T. Vuong et at. I.J. Rad Onc. Bio. Phys vol60:no1 supp; 2004 abst: 1062
Comparative tumor sterilization rate
by treatment modality
TREATMENT
pCR
(pMic)
RO
EBRT alone
7.1% (26%)
40%
CT+ EBRT
13% (31%)
60%
EBRT+contact
21% (60%)
NA
HDR alone
29% (66%)
97%
CT+EBRT+
HDR boost
40%? (80%)
100?
Treatment Options
• Surgery
T1/T2/T3 / N+
(clear CRM)
• Pre op chemo RT
r CRM <1mm
(sphincter preservation)
• Post op chemo RT
p CRM<1mm
(node +ive)
• Radical RT
T1/T2/ N0
Conclusions-1
• All cases with rectal cancer should be
discussed at the MDT
• MRI scan is essential for pre operative
assessment
• Pre operative chemoradiotherapy offers
better local control than pre operative
radiotherapy alone
Conclusions-2
• Pre operative chemoradiotherapy is more
effective and less toxic than post operative
chemoradiotherapy
• Nearly half the patients with rectal cancer
will develop recurrences; however no DFS
or overall survival benefit has been shown
with adjuvant chemotherapy in any of the
trials published so far.
It is important to
contribute to clinical
trials
Related documents